 BOSTON, Sept. 02, 2021 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Companys management team will be presenting at the following investor conferences: 